Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Both use SNAC technology to survive stomach acid and reach the bloodstream
Filed Under: Biologics, Dermatology, Immunology, Infectious Disease, Metabolic disease/endicrinology, Oncology Tagged With: AbbVie, biologic drugs, biosimilar competition, drug sales H1 2025, Eli Lilly, GLP-1 drugs, IL-23 inhibitors, immunology drugs, Keytruda patent expiry, loss of exclusivity, Merck, Novo Nordisk, obesity drugs, Oncology Therapeutics, patent cliff 2028, PD-1 inhibitors, pharmaceutical blockbusters, prescription drug market, Skyrizi, therapeutic categories Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
Dual agonists can blunt thirst perception, and dehydration worsens side effects like constipation, fatigue, and headaches
Because of the potentially significant risks associated with compounded semaglutide products, the FDA strongly recommends using an FDA-approved semaglutide drug like Wegovy when it is available
![glp-1 vs glp-3 difference what is glp 1 2 and 3 GLP-3: What's the difference? GLP Structure of [ 3 H]liraglutide –](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3897706330576071931)
